Description
Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice
€2.42
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€2.42 Add to cart -
Article: Highlights in digestive oncology
€2.42 Add to cart -
Article: Highlights in gynaecological cancers
€2.42 Add to cart -
Article: Highlights in urologic cancer
€2.42 Add to cart
